Third View Private Wealth
LGND icon

Third View Private Wealth’s Ligand Pharmaceuticals LGND Stock Holding History

Third View Private Wealth’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$240K Buy
769
+2
+0.3% +$591 0.03% 251
2026
Q2 		$242K Buy
+767
New +$181K 0.03% 273

Other funds holding LGND

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Ranger Investment Management
Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Third View Private Wealth's LGND Position: Q3 2026 in Review

Third View Private Wealth increased its Ligand Pharmaceuticals (LGND) stake by 0.26% in Q3 2026, buying an estimated $591 and bringing the position to 769 shares worth $240K. The position accounts for 0.03% of the portfolio, ranked #251.

Third View Private Wealth first reported a position in LGND in Q2 2026 and has held it in 2 quarters since. The position peaked at $242K in Q2 2026. 194 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Third View Private Wealth held 769 shares of Ligand Pharmaceuticals worth $240K as of Q3 2026.
  • Third View Private Wealth bought 2 Ligand Pharmaceuticals shares in Q3 2026, an estimated $591.
  • Ligand Pharmaceuticals made up 0.03% of Third View Private Wealth's portfolio in Q3 2026, its #251 holding.
  • Third View Private Wealth first reported a position in Ligand Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Third View Private Wealth's Ligand Pharmaceuticals position peaked at $242K in Q2 2026.
  • 194 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Third View Private Wealth's 13F filing for Q3 2026, filed 30 Oct 2026.